

Laura Mourino-Alvarez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4276424/publications.pdf>

Version: 2024-02-01

29
papers

436
citations

759233

12
h-index

752698

20
g-index

31
all docs

31
docs citations

31
times ranked

766
citing authors

#	ARTICLE	IF	CITATIONS
1	The Influence of Coronary Artery Disease in the Development of Aortic Stenosis and the Importance of the Albumin Redox State. <i>Antioxidants</i> , 2022, 11, 317.	5.1	6
2	Prioritization of Candidate Biomarkers for Degenerative Aortic Stenosis through a Systems Biology-Based In-Silico Approach. <i>Journal of Personalized Medicine</i> , 2022, 12, 642.	2.5	0
3	Diabetes Mellitus and Its Implications in Aortic Stenosis Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6212.	4.1	7
4	Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 602-617.	5.4	9
5	Comprehensive Proteomic Profiling of Pressure Ulcers in Patients with Spinal Cord Injury Identifies a Specific Protein Pattern of Pathology. <i>Advances in Wound Care</i> , 2020, 9, 277-294.	5.1	5
6	Patient Management in Aortic Stenosis: Towards Precision Medicine through Protein Analysis, Imaging and Diagnostic Tests. <i>Journal of Clinical Medicine</i> , 2020, 9, 2421.	2.4	2
7	Why Does COVID-19 Affect Patients with Spinal Cord Injury Milder? A Case-Control Study: Results from Two Observational Cohorts. <i>Journal of Personalized Medicine</i> , 2020, 10, 182.	2.5	5
8	Effects of Growth Hormone Treatment and Rehabilitation in Incomplete Chronic Traumatic Spinal Cord Injury: Insight from Proteome Analysis. <i>Journal of Personalized Medicine</i> , 2020, 10, 183.	2.5	3
9	Novel molecular plasma signatures on cardiovascular disease can stratify patients throughout life. <i>Journal of Proteomics</i> , 2020, 222, 103816.	2.4	5
10	Proteomic investigations into hypertension: what's new and how might it affect clinical practice?. <i>Expert Review of Proteomics</i> , 2019, 16, 583-591.	3.0	3
11	Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals. <i>Scientific Reports</i> , 2018, 8, 4802.	3.3	8
12	A comprehensive study of calcific aortic stenosis: from rabbit to human samples. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	2.4	6
13	Plasma proteomic profiling to stratify cardiovascular risk in young population. <i>Atherosclerosis</i> , 2017, 263, e192.	0.8	0
14	Recent advances and clinical insights into the use of proteomics in the study of atherosclerosis. <i>Expert Review of Proteomics</i> , 2017, 14, 701-713.	3.0	6
15	A clinical perspective on the utility of alpha 1 antichymotrypsin for the early diagnosis of calcific aortic stenosis. <i>Clinical Proteomics</i> , 2017, 14, 12.	2.1	14
16	Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria. <i>Oncotarget</i> , 2017, 8, 15553-15562.	1.8	20
17	MALDI-Imaging Mass Spectrometry: a step forward in the anatomopathological characterization of stenotic aortic valve tissue. <i>Scientific Reports</i> , 2016, 6, 27106.	3.3	39
18	Patients with calcific aortic stenosis exhibit systemic molecular evidence of ischemia, enhanced coagulation, oxidative stress and impaired cholesterol transport. <i>International Journal of Cardiology</i> , 2016, 225, 99-106.	1.7	34

#	ARTICLE	IF	CITATIONS
19	Plasma Molecular Signatures in Hypertensive Patients With Renin-Ângiotensin System Suppression. <i>Hypertension</i> , 2016, 68, 157-166.	2.7	18
20	Cytoskeleton deregulation and impairment in amino acids and energy metabolism in early atherosclerosis at aortic tissue with reflection in plasma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 725-732.	3.8	35
21	iTRAQ proteomic analysis of extracellular matrix remodeling in aortic valve disease. <i>Scientific Reports</i> , 2015, 5, 17290.	3.3	36
22	KLK1 and ZG16B proteins and arginine-proline metabolism identified as novel targets to monitor atherosclerosis, acute coronary syndrome and recovery. <i>Metabolomics</i> , 2015, 11, 1056-1067.	3.0	35
23	Contribution of proteomics to the management of vascular disorders. <i>Translational Proteomics</i> , 2015, 7, 3-14.	1.2	3
24	Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics. <i>International Journal of Cardiology</i> , 2015, 196, 170-177.	1.7	18
25	Plasma metabolomics reveals a potential panel of biomarkers for early diagnosis in acute coronary syndrome. <i>Metabolomics</i> , 2014, 10, 414-424.	3.0	45
26	The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome. <i>Proteome Science</i> , 2014, 12, 43.	1.7	5
27	Proteomic characterization of EPCs and CECs -in vivo- from acute coronary syndrome patients and control subjects. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 3030-3053.	2.4	10
28	Potential blood biomarkers for stroke. <i>Expert Review of Proteomics</i> , 2012, 9, 437-449.	3.0	28
29	Inside human aortic stenosis: A proteomic analysis of plasma. <i>Journal of Proteomics</i> , 2012, 75, 1639-1653.	2.4	31